{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:32:34Z","timestamp":1777617154043,"version":"3.51.4"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study aimed to evaluate the effects of torsemide on warfarin therapy in humans and rats.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>For the animal study, rats were orally dosed with warfarin (0.13 mg\/kg, control group) or warfarin (0.13 mg\/kg) with torsemide (2 mg\/kg, low dose group and 10 mg\/kg, high dose group). The pharmacodynamic response of warfarin was assessed by measuring the international normalized ratio (INR) for 5 consecutive days following drug administration. For the human study, 191 patients on warfarin with mechanical heart valves were followed up retrospectively. The stable dose was calculated as the mean dose in INR levels of 2\u20133 for 3 consecutive times.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>In the animal study, the INR, maximum plasma concentration (Cmax) and area under the plasma drug concentration\u2013time curve (AUC0\u2013\u221e) of (S)-warfarin in the high dose group were significantly higher than in other groups (P &amp;lt; 0.05). Compared with the control group, Cmax and AUC0\u2013\u221e of (R)-warfarin in the high and low dose groups were higher, whereas the volume of distribution\/bioavailability and clearance\/bioavailability were significantly lower (P &amp;lt; 0.05). In the univariate analysis of the clinical study, diuretics significantly lowered stable warfarin doses (P = 0.016) (5.07 \u00b1 1.78 mg\/day vs 5.77 \u00b1 1.81 mg\/day). After controlling confounding variables, the effects of diuretics were found to lower the warfarin dose by 0.464 mg.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>It was concluded that warfarin dose needs to be lowered when it is used concomitantly with diuretics.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jphp.12084","type":"journal-article","created":{"date-parts":[[2013,5,29]],"date-time":"2013-05-29T06:20:22Z","timestamp":1369808422000},"page":"1195-1203","source":"Crossref","is-referenced-by-count":4,"title":["Effects of torsemide on pharmacodynamics and pharmacokinetics of warfarin in humans and rats"],"prefix":"10.1093","volume":"65","author":[{"given":"Han Oll","family":"Kim","sequence":"first","affiliation":[{"name":"College of Pharmacy & Division of Life and Pharmaceutical Sciences, Ewha Womans University , Seoul,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Eun","family":"Lee","sequence":"additional","affiliation":[{"name":"College of Pharmacy & Division of Life and Pharmaceutical Sciences, Ewha Womans University , Seoul,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Yoon","family":"Park","sequence":"additional","affiliation":[{"name":"College of Pharmacy & Division of Life and Pharmaceutical Sciences, Ewha Womans University , Seoul,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na Ra","family":"Lee","sequence":"additional","affiliation":[{"name":"College of Pharmacy & Division of Life and Pharmaceutical Sciences, Ewha Womans University , Seoul,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byeou Ree","family":"Oh","sequence":"additional","affiliation":[{"name":"College of Pharmacy & Division of Life and Pharmaceutical Sciences, Ewha Womans University , Seoul,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung Chul","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Thoracic & Cardiovascular Surgery, Yonsei University Medical Center , Seoul,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Sun","family":"Gwak","sequence":"additional","affiliation":[{"name":"College of Pharmacy & Division of Life and Pharmaceutical Sciences, Ewha Womans University , Seoul,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,8,1]]},"reference":[{"key":"2024103109171669000_jphp12084-cit-0001","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.amjmed.2003.12.036","article-title":"Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols","volume":"116","author":"Franco","year":"2004","journal-title":"Am J Med"},{"key":"2024103109171669000_jphp12084-cit-0002","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cca.2008.07.005","article-title":"Genetic factors contribute to patient-specific warfarin dose for Han Chinese","volume":"396","author":"Wang","year":"2008","journal-title":"Clin Chim Acta"},{"key":"2024103109171669000_jphp12084-cit-0003","volume-title":"Drug Information Handbook","author":"Lacy","year":"2008","edition":"17th edn"},{"key":"2024103109171669000_jphp12084-cit-0004","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/clpt.2008.166","article-title":"Pharmacogenetics of warfarin: development if a dosing algorithm for Brazilian patients","volume":"84","author":"Perini","year":"2008","journal-title":"Clin Pharmcol Ther"},{"key":"2024103109171669000_jphp12084-cit-0005","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1248\/bpb1978.5.829","article-title":"Effect of furosemide on plasma clearance, anticoagulant effect and protein binding of warfarin in rats","volume":"5","author":"Ogiso","year":"1982","journal-title":"J Pharmacobiodyn"},{"key":"2024103109171669000_jphp12084-cit-0006","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1345\/aph.1L306","article-title":"Probable interaction between warfarin and torsemide","volume":"42","author":"Bird","year":"2008","journal-title":"Ann Pharmacother"},{"key":"2024103109171669000_jphp12084-cit-0007","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/j.1552-4604.1978.tb02426.x","article-title":"The effect of furosemide and bumetanide on warfarin metabolism and anticoagulant response","volume":"18","author":"Nilsson","year":"1978","journal-title":"J Clin Pharmacol"},{"key":"2024103109171669000_jphp12084-cit-0008","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/jcp.38.2.133","article-title":"ICSH\/ICTH recommendations for reporting prothrombin time in oral anticoagulant control","volume":"38","author":"International Committee for Standardization in Haematology and International Committee on Thrombosis and Haemostasis","year":"1985","journal-title":"J Clin Pathol"},{"key":"2024103109171669000_jphp12084-cit-0009","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0731-7085(00)00232-6","article-title":"Validation of a method for the determination of (R)-warfarin and (S)-warfarin in human plasma using LC with UV detection","volume":"22","author":"Ring","year":"2000","journal-title":"J Pharm Biomed Anal"},{"key":"2024103109171669000_jphp12084-cit-0010","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1023\/A:1015882607690","article-title":"Validation of bioanalytical methods","volume":"8","author":"Kamas","year":"1991","journal-title":"Pharm Res"},{"key":"2024103109171669000_jphp12084-cit-0011","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2217\/14622416.10.2.261","article-title":"CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population","volume":"10","author":"Borgiani","year":"2009","journal-title":"Pharmacogenomics"},{"key":"2024103109171669000_jphp12084-cit-0012","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1182\/blood-2007-11-122010","article-title":"CYP4F2 genetic variant alters required warfarin dose","volume":"111","author":"Caldwell","year":"2008","journal-title":"Blood"},{"key":"2024103109171669000_jphp12084-cit-0013","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.thromres.2006.09.007","article-title":"Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients","volume":"120","author":"Kimura","year":"2007","journal-title":"Thromb Res"},{"key":"2024103109171669000_jphp12084-cit-0014","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/clpt.2009.178","article-title":"Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients","volume":"87","author":"Pautas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"2024103109171669000_jphp12084-cit-0015","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1182\/blood-2008-09-176222","article-title":"Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy","volume":"113","author":"P\u00e9rez-Andreu","year":"2009","journal-title":"Blood"},{"key":"2024103109171669000_jphp12084-cit-0016","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood-2003-09-3043","article-title":"Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factor II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity","volume":"103","author":"Shikata","year":"2004","journal-title":"Blood"},{"key":"2024103109171669000_jphp12084-cit-0017","doi-asserted-by":"crossref","first-page":"e1000433","DOI":"10.1371\/journal.pgen.1000433","article-title":"A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose","volume":"5","author":"Takeuchi","year":"2009","journal-title":"PLoS Genet"},{"key":"2024103109171669000_jphp12084-cit-0018","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/clpt.2009.291","article-title":"A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans","volume":"87","author":"Voora","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"2024103109171669000_jphp12084-cit-0019","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2008-04-149070","article-title":"The largest prospective warfarin-treated cohort supports genetic forecasting","volume":"113","author":"Wadelius","year":"2009","journal-title":"Blood"},{"key":"2024103109171669000_jphp12084-cit-0020","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/cpt1974154424","article-title":"Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man","volume":"15","author":"Breckenridge","year":"1974","journal-title":"Clin Pharmacol Ther"},{"key":"2024103109171669000_jphp12084-cit-0021","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/cpt1974162348","article-title":"Studies on the optical enantiomorphs of warfarin in man","volume":"16","author":"O'Reilly","year":"1974","journal-title":"Clin Pharmacol Ther"},{"key":"2024103109171669000_jphp12084-cit-0022","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0021-9673(00)91155-5","article-title":"Study of binding of low-molecular-weight ligand to biological macromolecules by high-performance liquid chromatography. Evaluation of binding parameters for two drugs bound to human serum albumin","volume":"167","author":"Sebille","year":"1978","journal-title":"J Chromatogr"},{"key":"2024103109171669000_jphp12084-cit-0023","first-page":"824","article-title":"Characterization of two specific drug binding sites on human serum albumin","volume":"11","author":"Sudlow","year":"1975","journal-title":"Mol Pharmacol"},{"key":"2024103109171669000_jphp12084-cit-0024","volume-title":"Clinical Pharmacokinetics: Concepts and Applications","author":"Rowland","year":"1995","edition":"3rd edn"},{"key":"2024103109171669000_jphp12084-cit-0025","first-page":"1","article-title":"Fundamentals of clinical pharmacology","volume-title":"Avery's Drug Treatment: A Guide to the Properties, Therapeutic Use and Economic Value of Drugs in Disease Management","author":"Sjoqvist","year":"1997"},{"key":"2024103109171669000_jphp12084-cit-0026","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/FTD.0b013e318256a77c","article-title":"Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves","volume":"34","author":"Lee","year":"2012","journal-title":"Ther Drug Monit"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12084","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12084","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/65\/8\/1195\/60253580\/jphp12084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/65\/8\/1195\/60253580\/jphp12084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T09:26:50Z","timestamp":1730366810000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/65\/8\/1195\/6132914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,1]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,8,1]]},"published-print":{"date-parts":[[2013,8,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.12084","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"value":"2042-7158","type":"electronic"},{"value":"0022-3573","type":"print"}],"subject":[],"published-other":{"date-parts":[[2013,8]]},"published":{"date-parts":[[2013,8,1]]}}}